Incidence and Prognosis of Brain Metastases in Head and Neck Cancer Patients at Diagnosis.
Brain metastases
head and neck cancer
national cancer database (NCDB)
stereotactic radiosurgery (SRS)
whole brain radiation therapy (WBRT)
Journal
The Laryngoscope
ISSN: 1531-4995
Titre abrégé: Laryngoscope
Pays: United States
ID NLM: 8607378
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
26
01
2021
received:
03
09
2020
accepted:
31
01
2021
pubmed:
19
2
2021
medline:
21
9
2021
entrez:
18
2
2021
Statut:
ppublish
Résumé
Limited data is available on head and neck cancer (HNC) patients presenting with brain metastases (BM) at initial diagnosis. We sought to evaluate the incidence, management, and treatment outcomes of these patients using the National Cancer Database (NCDB). We identified 465,925 patients diagnosed with HNC between 2010 and 2015 in the NCDB. 14,583 of these patients presented with metastatic disease to any site. 440 of these patients had BM at the time of initial diagnosis. Overall survival was compared using the Kaplan-Meier method. Cox proportional hazard modeling, propensity score matching, and subgroup analyses were performed. The median age overall was 62.0 years. Nasopharynx NOS (13.2%) and Parotid Gland (10.9%) were the most common anatomical sites with the highest frequency of BM. The overall median survival time was 7.1 months. Predictors for the presence of BM included distant metastasis to the bone, liver, or lung on univariate analysis, and bone or lung on multivariate analysis. High-risk Human Papilloma Virus status was associated with a lower chance of BM. No pattern was determined when comparing lymph node level involvement and BM. The median survival for patients receiving radiation therapy and multi-agent chemotherapy was 8.4 and 11.7 months, respectively. Immunotherapy administered as first course therapy did not influence median survival. Most patients received radiation (62.7%) therapy and chemotherapy (50.2%). The data extracted and analyzed from the NCDB should work to aid in the surveillance and management of BM in patients with HNC. 4 Laryngoscope, 131:E2543-E2552, 2021.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
E2543-E2552Informations de copyright
© 2021 The American Laryngological, Rhinological and Otological Society, Inc.
Références
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7-34.
Ridge JA, Mehra R, Lango MN, Galloway T. Head and neck tumors. Cancer network 2016.
Kotwall C, Razack MS, Sako K, Rao U. Multiple primary cancers in squamous cell cancer of the head and neck. J Surg Oncol 1989;40:97-99.
Goyal S, Silk AW, Tian S, et al. Clinical management of multiple melanoma brain metastases: a systematic review. JAMA Oncol 2015;1:668-676.
Patel RA, Bell JB, Kim T, et al. Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis. J Neurooncol 2017;134:197-203.
Caffo O, Gernone A, Ortega C, et al. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol 2012;107:191-196.
Mongan JP, Fadul CE, Cole BF, et al. Brain metastases from colorectal cancer: risk factors, incidence, and the possible role of chemokines. Clin Colorectal Cancer 2009;8:100-105.
Barrett TF, Gill CM, Miles BA, et al. Brain metastasis from squamous cell carcinoma of the head and neck: a review of the literature in the genomic era. Neurosurg Focus 2018;44:E11.
Ghosh-Laskar S, Agarwal JP, Yathiraj PH, et al. Brain metastasis from nonnasopharyngeal head and neck squamous cell carcinoma: a case series and review of literature. J Cancer Res Ther 2016;12:1160-1163.
Cagney DN, Martin AM, Catalano PJ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol 2017;19:1511-1521.